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ABSTRACT
The role of protein structural ensembles has been shown to be very important
for different physical and chemical properties of proteins. The work presented in this
dissertation explores two of these properties:
i) Thermostability, by characterizing, at three different temperatures, the
dynamics of aminoglycoside nucleotidyltransferase 4’ (ANT). This homodimeric
enzyme detoxifies antibiotics. It possess two known variants, D80Y and T130K, with
higher melting temperatures than the wild type. These mutations, however, would
cause changes in the distributions of conformations in the ensemble and,
consequently, on the dynamics of the protein. To test this hypothesis, the wild type
and variants were examined by using molecular dynamics simulations and the results
were compared with previous experimental information in order to characterize the
similarities and differences between the, so-called, thermophilic and thermostable
variants of this enzyme.
ii) Ligand binding: Since proteins are in general dynamic structures, it would
be expected that the effectiveness of ligand binding varies as the protein’s
conformation changes. One of the most targeted protein family in the field of drug
discovery/design is the G-Protein Coupled Receptor (GPCR) family. Over 30% of
approved drugs target this family of proteins. This project examines, via in silico
experiments, the differences in ligand binding between different conformations of
GPCRs. To this end, GPCR ligand structures, actual binding (actives) and nonbinding (decoys) ligands, were obtained from public databases, and eight GPCRs
structures were selected to generate 5,000 conformational states for each protein.
Ensemble-based docking was performed on representative structures of these 5,000
conformers and on a subset of 3,000 conformers from each of the eight proteins.
Decoys and statistical analysis were incorporated in the docking simulations to test
whether the sampled protein conformations can bind active ligands in greater
numbers than the random selection from the pool of active and decoys. The results
v

show that some conformations bind more ligands than other conformations, random
selection, or the crystal structure. Characterizing the entire ensemble of protein
conformations can improve the number of bound active ligands identified
computationally, compared to random selection of compounds or docking using only
a single crystal structure.
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INTRODUCTION
Protein Structure Ensembles
The structure-function relationship theory, in which the 3D structure of protein
defines function, was bolstered by the availability of high-resolution structures of
proteins. Since then, the idea that proteins can be defined by one unique structure,
the “right folded state”, prevailed for a few decades. However, the idea of a
relationship between energy-landscape and function was proposed by Frauenfelder
in the 70's (Austin, Beeson, Eisenstein, Frauenfelder, & Gunsalus, 1975), when this
group observed a correlation between the non-exponential kinetics of carbon
monoxide and oxygen rebinding to myoglobin and the energy barrier produced by
temperature and ligand concentration. Previous observations on myoglobin between
the late 1880's and early 1920's, supported this concept, and protein dynamics as a
factor affecting its function became more accepted. This led to the idea that structural
states are in thermal equilibrium while at the same time solvent and ligands affect the
energy landscape, and the population of conformational states (Frauenfelder,
Fenimore, & McMahon, 2002; Loncharich & Brooks, 1990). These results on
myoglobin and other proteins, e.g. Dihydrofolate Reductase, in which conformational
substates modulate the transference rate of hydride (Thorpe & Iii, 2005), led to the
idea that proteins exist as ensembles of similar structures. These transient
microstates interconvert between each other, and the average of these conformers
are resolved by high-resolution techniques, such as crystallography and NMR
spectroscopy. The concept of native states as a set of structural conformations or
microstates provide a basis to rationalize the physical-chemical properties of proteins
such as stability, solubility, affinity, binding, and specificity/promiscuity for ligands as
function of these structural ensembles. Thus, biological features of proteins are the
result of an energy-weighted contribution from each conformer in the ensemble
(Hilser, Garcia-Moreno E., Oas, Kapp, & Whitten, 2006).
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The striking improvement of molecular dynamics (MD) simulations since the
first reported work in the late 70's (McCammon, Gelin, & Karplus, 1977) has been
due to the increase of computational power as well as improvement of potential
energy functions. This allows the generation of conformational changes in proteins
on time scales that go from femtoseconds to milliseconds. This range of timescales
comprises atomic fluctuations, side chains rotations, loop motions, and large domain
motions (Henzler-Wildman & Kern, 2007). The combination of all these motions at
different time scales will result in many possible conformational structures, which will
be part of the ensemble at particular conditions, e.g., temperature, salt concentration,
protonation states, bound-ligand, free-ligand. Thus, MD simulations are tools
employed to build ensembles of conformational states for any protein for which a
structure in available.

About the work developed in this dissertation
Chapter 1 describes the work done on aminoglycoside nucleotidyltransferase 4’
(ANT) to study its thermostability. MD simulations at three temperatures were
performed for the wild type and two variants, D80Y and T130K. The flexibility of the
protein has been analyzed by applying principal component analysis (PCA) to the
trajectories obtained from the MD simulations. PCA allows the deconvolution of the
main modes of motion, thus, it is possible to find out which regions in the protein
have the largest amplitude motions, their directions, and how these motions
contribute to the formation of protein structure ensembles (Jing, Evangelista Falcon,
Baudry, & Serpersu, 2017).
Chapter 2 describes the development of a protocol to perform ensemblebased docking on G-Protein Coupled Receptors (GPCRs) preventing false positives.
This is particularly important in the field of drug discovery and design, because when
a new potential drug is tested, this new molecule must be able to bind at least one of
the conformers present in the population of the target protein’s structure. Otherwise,
2

the binding affinity may be too low to be effective under physiological conditions. Four
GPCRs were used in a more exhaustive study of conformational selection.
Conformations for each protein ensemble were generated via Coarse-Grained (CG)
MD simulations. Molecular docking was then performed by using VinaMPI (Ellingson,
Smith, & Baudry, 2013). The most important contribution of this project is the
incorporation of the statistical concept of ‘outliers’ as a threshold to determine
whether a conformational state is significant beyond random selection its capacity to
be selected by the protein ligands.
Chapter 3 proposes future directions in the field of drug discovery and design by
using ensemble-based docking simulations as has been previously suggested
(Evangelista et al., 2016). The formulation of a reliable protocol to perform such
simulations becomes imperative in order to test not only the binding to target
proteins, but also off-target proteins. This kind of in silico experiments can also be
applied to predict adverse drug reactions.
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CHAPTER I
RELATIONSHIP BETWEEN STRUCTURE ENSEMBLE AND
THERMOSTABILITY OF AMINOGLYCOSIDE
NUCLEOTIDYLTRANSFERASE 4′
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Evangelista Falcón, Jerome Baudry, Engin Serpersu:
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Abstract
Aminoglycoside nucleotidyltransferase 4′ (ANT) is a homodimeric enzyme that
modifies the C4′-OH site of aminoglycoside antibiotics by nucleotidylation. A few
single- and double-residue mutants of this enzyme (T130K, D80Y, and D80Y/T130K)
from Bacillus stearothermophilus show increased thermostability. Our main interest is
to study the structural changes of this enzyme as result of mutations and variation in
the temperature. Three systems were prepared based on the crystal structure of the
mutant D80Y, WT and T130K. MD simulations on these three systems at 300K,
322K, and 330K were performed for 100 ns each one, in total 900 ns of production
time, i.e. three systems at three different temperatures.

Introduction
Thermophilic enzymes are exclusively produced by Archea and Bacteria inhabiting
natural hot environments, such as volcanic pools, hot springs, or any other natural
7

hot environment. These organisms’ enzymes have a property called thermostability,
namely, these enzymes can perform their activity at temperatures higher than 50 °C
and up to 110°C. Due to this wide range of temperatures, such enzymes have been
classified as thermophilic, performing their function in the at 50-80 °C range and
hyperthermophilic in the 80-110 °C range, while regular enzymes, mesophilic,
function in the 20-40 °C range (Danson, Hough, Russell, Taylor, & Pearl, 1996;
Fields, 2001). ANT belongs to the thermophilic category and has been isolated from
mesophile bacteria, Staphylococcus aureus, in a genetic study (Lacey & Chopra,
1973). Studies on induced thermostable variants and screening for aminoglycosides
resistant mutants were developed in the 80's (Liao, McKenzie, & Hageman, 1986;
Matsumura & Aiba, 1985), two single mutants were identified as thermophilic, D80Y
and T130K; as well as the double mutant D80Y/T130K.

Figure I.1 Crystal Structure of variant D80Y.
PDB structure with bound ligands (Pedersen, Benning, & Holden, 1995), chains are
colored in green and cyan. MgATP analog (purple) and kanamycin A (red) are bound
to the active site, which is formed at the interface of monomers. Residues D80 (blue)
and T130 (yellow) are shown as ball and stick model.
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Methods
Molecular Dynamics
Systems were constructed based on the crystal structure of the D80Y species
(Protein Data Bank ID: 1KNY) using Molecular Operating Environment (MOE, version
2012, Chemical Computing Group, Ltd, Montréal, Canada). The co-crystalized ligand
and cofactor were removed from the model such that the apo form of the wild type,
and T130K species were built by performing the correspondent mutations on the
crystal structure of D80Y. Each structure was explicitly solvated with the TIP3P water
model in a cubic box of 8 nm x 8 nm x 8 nm. Periodic Boundary Conditions in all
directions were applied with electrostatic type Fast smooth Particle Mesh Ewald
(PME). A18,000-step energy minimization was performed using the steepest decent
algorithm. Molecular Dynamics simulations were carried out using the Gromacs 4.6.1
(Berendsen, Vanderspoel, & Vandrunen, 1995; Hess, 2008) simulation engine and
the AMBER-f99sb (Hornak et al., 2006) force field. For each species at different
temperatures, 300K, 322K, and 330K, a 50 ns equilibration with a 2fs integration
timestep was performed in the isothermal-isobaric ensemble (NPT), and 1 bar
pressure using the Nosé-Hoover temperature control (Hoover, 1985; Nose, 1984)
and the Berendsen weak coupling pressure control (Berendsen, Postma, van
Gunsteren, DiNola, & Haak, 1984). Finally, a 100 nanoseconds production run was
performed using the Panirello-Rahman algorithm (Parrinello & Rahman, 1981).
Atomic coordinates of the trajectory were saved on disk every 5 ps.
Principal Component Analysis
The trajectories obtained from the production run were analyzed using a built-in
Gromacs tool, Principal Component Analysis (PCA). This method allows identification
of the main modes of motions in the protein, highlighting the different conformational
changes in the molecule (Tournier & Smith, 2003). Since these main motions can be
described by the first principal components, this method is also called “essential
9

dynamics” (Amadei & Limddrn, 1993). As a first step before applying this method, the
trajectory has to be preprocessed; rotation and global translational motions must be
removed by carrying out a coordinate root mean square best-fit to a reference
structure, for instance, an average structure. Then, the coordinates as a function of
time are stored in the matrix R with 3N rows containing the coordinates of the N
atoms and M columns holding successive time points of the trajectory. Next, the
covariance matrix C is calculated as in equation 1.1, for every atom from the group

subject to analysis. Then, matrix C is diagonalized to obtain the set of eigenvectors V
and their associated eigenvalues λi.

𝐶𝐶 =

𝑅𝑅𝑅𝑅 𝑇𝑇

(1.1)

3𝑁𝑁

(1.2)

diag(λ1, λ2, …,λn) = VTCV

The 3N-6 eigenvectors in V describe the orthogonal concerted motions of the protein.

The variance in the original data is given by the eigenvalues and the direction of this
variance by their associated eigenvectors in equation 1.2. Thus, any conformation of
the

protein

whose

coordinates

are

in

the

cartesian

space

𝑅𝑅 (𝑟𝑟̅1 , 𝑟𝑟̅2 , … 𝑟𝑟̅𝑁𝑁 ) maps onto a point 𝑄𝑄 (𝑞𝑞�1 , 𝑞𝑞�2 , … 𝑟𝑟̅3𝑁𝑁−6 ) in the eigenvector space V. The

qi coefficients are the projections of R onto the eigenvectors space. This is just a

transformation of the coordinate system, thus, the original and projected coordinates
hold back the same information. To map a particular point Q from the eigenvector
space to the cartesian coordinate system R it is necessary to calculate the average

structure <S> in the R space and add the appropriate linear combination of qi and the
eigenvector basis 𝑣𝑣̅𝑖𝑖 , as shown in equation 1.3

3𝑁𝑁−6
𝑅𝑅 =< 𝑆𝑆 > + ∑𝑖𝑖=1
𝑞𝑞𝑖𝑖 . 𝑣𝑣̅1

(1.3)

In order to identify the main modes of motion in the protein, the eigenvalues should
be sorted in descending order, then, plotting these eigenvalues against their indexes
will commonly show that only the few first eigenvectors, those with the largest
magnitudes, are responsible for the major motions in the protein. Therefore, the
10

variance of the protein structure and dynamics can be described by just a few modes,
the motions along their associated eigenvectors dominate the dynamics of the protein
and contain most of the global dynamic information. To capture conformational
changes in the secondary or tertiary structure of the protein it is necessary and
sufficient to analyze the Cα atoms of the molecule, those atomic coordinates as a
function of time are stored in matrix R, as in the equation 1, which is used to generate
the covariance matrix C. PCA was performed on the trajectory obtained from the MD

simulations to identify the main dynamic modes for the three species, WT, T130K,
and D80Y at three different temperatures: 300K, 322K, and 330K.
Free Energy Landscape of the Structural Ensemble
While it is true PCA identifies the main motions of the structures and how they vary
with species and temperature, it is not enough to analyze how the protein structure
ensemble changes as a result of mutations and/or increase of temperature. In order
to examine the change in the ensemble of conformations a method to characterize
the different conformations must be selected. Usually conformers can be
characterized by using geometric parameters, distances, angles, root mean square
deviations, etc., however, this kind of parameters usually misses changes in other
regions of the protein that could define a new conformation (Hall, Kaye, Pang,
Perera, & Biggin, 2007). Principal components [v1,v2,…,vN], on the other hand, can
detect concerted motions, even though they are not parallel or antiparallel, giving an
appropriate representation of the protein dynamics. Thus, the full set of eigenvectors
over the trajectory can describe the different conformations sampled during the MD
simulation. In general, when a set of parameters S =[s1,s2,…,sn], at the temperature T,

can depict a particular configuration of the system, it is possible to calculate the
probability function P(s1,s2,…,sn,T) from a histogram of the MD trajectory for each

combination of values of si at the temperature T. The free energy landscape (FEL) of

a system like this is a potential of mean force (PMF), ∆𝑊𝑊(s1,s2,…,sn,T) , (Grubmüller &
Tavan, 1994; Rice & Gray Peter, 1965):
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(1.4)

∆𝑊𝑊(s1,s2,…,sn,T) = − 𝑘𝑘𝛽𝛽 𝑇𝑇 �ln 𝑃𝑃(𝑠𝑠1,𝑠𝑠2,..,𝑠𝑠𝑠𝑠,𝑇𝑇) − ln(𝑃𝑃𝑚𝑚𝑚𝑚𝑚𝑚 )�

Where kβ is the Boltzmann constant, and Pmax the maximum probability in the

distribution, which is included in the equation as subtracting to make sure that

∆𝑊𝑊(s1,s2,…,sn,T) = 0 for the lowest free energy value. Although, the high-dimensional

space S is needed to characterize protein conformations, it is possible to reduce

these dimensions and only use those parameters that describe the majority of the
change in the structure. Thus, in this particular case, given the first two eigenvectors
[e1, e2], the projections of the data r onto them will

[v1,v2] will be employed as

conformation coordinates at temperature T to calculate the probability function
𝑃𝑃(𝑣𝑣1,𝑣𝑣2,𝑇𝑇) and PMF ∆𝑊𝑊(𝑣𝑣1,𝑣𝑣2,𝑇𝑇) , Equation 1.5,

of the distribution of the conformers

sampled by the MD simulations (Grubmüller & Tavan, 1994; Mu, Nguyen, & Stock,
2005; Papaleo, Mereghetti, Fantucci, Grandori, & De Gioia, 2009).
∆𝑊𝑊(𝑣𝑣1,𝑣𝑣2) = − 𝑘𝑘𝛽𝛽 𝑇𝑇 �ln 𝑃𝑃(𝑣𝑣1,𝑣𝑣2,𝑇𝑇) − ln(𝑃𝑃𝑚𝑚𝑚𝑚𝑚𝑚 )�

(1.5)

From these equations, it is clear that low values of PMF, ∆W, correspond to high
probability configurations, which implies that high probability regions in the
conformational space are more stable thermodynamically than regions with low
probability. Thus, for this particular case at a given temperature T, a free energy
landscape can be generated as a function of the first two eigenvectors. Figure I.4
shows the FEL for the three species at three different temperatures.
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Results and Discussion
Principal Component Analysis of the MD trajectories
Analysis of the 300K simulation data suggests that the global dynamics of D80Y is
dominated by the first dynamic mode (Figure I.2 right panel), whereas at 322K and
330K the first two modes both contribute significantly to the global protein dynamics.
The dynamics of the WT and T130K species are mainly due to the contribution of the
first two modes at all temperatures studied here as shown in Figure I.2 (left and
middle panels), although the first mode of motion contributes more at 330K. The
orientation and amplitude of the first two modes for WT, T130K, and D80Y at 300K
are shown by vectors in Figure I.3 (left panel). The origin of these vectors indicates
the region of the protein undergoing motion in those particular vectors’ direction. The
left set in each set of these figures show the motion due to the first mode of the
protein. The first mode corresponds to the same dominant movement in the three
species: an open/close “breathing” motion. The difference between the dynamics of
the three species at different temperatures originates from the second dynamics
mode, the WT and T130K variants display similar contributions in magnitude, but the
regions impacted by this mode are different as well as the direction of the motion
(right sets in each panel of Figure I.3). The D80Y species, exhibit a significant
contribution only at 322K and 330K from this mode of motion. These results suggest
that the first mode of motion has the same direction at all temperatures for all the
three species (left sets in each panel of Figure I.3). The difference seems to arise
from the second mode, whose vectors have different origins and directions
depending on the species (right sets in each panel of Figure I.3). For instance, at 330
K, D80Y exhibits a very different second dynamics mode, magnitude and directions
are different compared to those form WT or T130K species (right sets in the right
panel of Figure I.3). These would suggest these point mutations, instead of causing
local structural changes, actually affect the global dynamic properties of the enzyme,
which in turn characterizes the mesophilic/thermophilic features of this protein.
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Figure I.2. Principal modes of motion of ANT.
Principal modes of motion projected onto the first 25 eigenvalues calculated from
PCA in MD trajectories at different temperatures; Left to right are WT, T130K, and
D80Y, respectively. Filled circles (blue), squares (green) and diamonds (red)
represent 300K, 322K and 330K respectively. The insets show expanded regions of
the several initial modes of motion.
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a. At 300K

b. 322K

c. 330K

Figure I.3. First and second mode of motion of the ANT structure.
The arrows, obtained from PCA, represent the first (left panel) and second mode (right panel) of motions respectively.
Top to bottom are: WT, T130K, and D80Y. C-α atoms of Asp80 and Thr130 are represented by orange and purple
spheres, respectively.
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Free Energy Landscape
In the previous section the first two modes of motions, PC1 and PC2, were used to
characterize the directions and magnitude of the motion of the enzyme, the different
values that these parameters can take are also useful to characterize the different
conformational changes that ANT can adopt. These components are useful to obtain
a two-dimensional free energy landscape according to Equation 1.5, at different
temperatures and for each species analyzed here. Figure I.4 shows how different
values of PC1 and PC2 lead to new conformational states of the protein, forming
clusters of conformations more thermodynamically stable as temperature increases
in the three species. The blue regions represent the most likely conformations at a
particular temperature, intermediate states are cyan and green, while red regions are
unaccessible states of the protein. WT at 330K shows that the most stable state is
around PC1= PC2 = 0, the blue spot, thus the stable conformations are grouped in
just one cluster, while at 322K, the breakup of the clusters is already noticeable, and
at 330K there are already two main clusters containing the most stable conformations
of the protein. The variant T130K, on the other hand, seems to have two clusters at
300K, and this starts splitting into two diffuse clusters at 322K. Finally three less
populated stable clusters seem to come up at 330K. The D80Y species shows a
specific behavior at 300K. There are three clusters, two of them well populated, the
third one less populated, but still well defined. This pattern changes when
temperature increases to 322K, with a single cluster centered at PC1 = PC2 = 0, very
similar to that of WT at 300K. At 330K this same cluster is visible, centered at the
same values of PC1 and PC2, with a slight variation at PC1 = 1.0 and PC2 = -1.0. In
other words, for this variant, the number of clusters decreases as temperature
increases and seems to be more stable at 322K than it is at 300K.
Analyzing Figure I.4, to investigate the effect of the mutations at a given temperature,
it appears that: at 300K the D80Y variant has three clusters, stable configurations,
while T130K shows two stable clusters, and WT only one cluster representing
16

thermodynamically

stable

conformations,

at

this

temperature

all

of

those

conformations in this cluster are thermodynamically stable. At 322K, the WT species
shows a cluster of conformations that would be thermodynamically very stable (blue
region), according to equation 1.5, however, there is a population of structures that,
though less stable, are still part of the ensemble (cyan region in the panel). The
T130K species displays one very populated cluster, however, there is also a nascent
set of stable conformations that eventually could become populated if the MD
simulations were longer. These two species, WT and T130K, seem to split the
clusters with respect to their ensemble at 300K probably due to their melting
temperatures being 314K and 322K, respectively. This implies that their structures at
room temperature will undergo changes when temperature increases to 322K,
forming other clusters. On the other hand, the cluster of stable structures is more
spread out for D80Y, PC1’s range is [-5.0; 4.5] and PC2’s [-2.5; 2.5], suggesting that
the transition between conformations happen through lower free energy barriers than
in the other species.
The situation at 330K is quite different, WT displays two well defined clusters, while
the T130K species possess one very populated cluster with two additional less
populated clusters, suggesting that this mutation enables the protein to keep one
stable cluster while shaping two other sets of conformations that may become more
populated as the sampling of the MD simulation increases. The case of D80Y is
different; the mutation in this case enables the protein to keep a centered cluster very
similar to that of WT’s at 300K. However, it also shows some nascent separation at
PC1=1.8 and PC2= -1.8, which might be explained by the 329K melting temperature
of this species.
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WT

T = 300K

T = 322K

T = 330K

T130K

D80Y

Figure I.4. Free energy landscape for the three species of ANT.
Energy landscape along the first two modes of motion for each species at the three
temperatures. Blue regions represent high-probability configurations, and therefore
more thermodynamically stable conformations. Yellow and orange regions denote
less populated configurations.
18

Conclusions
Thermophilic proteins use different strategies to reach thermal adaptation.
Comparisons between mesophilic and thermophilic proteins have been published,
and difference between these enzymes have been attributed to side-chain hydrogen
bonds, salt bridges, and internal hydrophobic packing (Dominy, Minoux, & Brooks,
2004; Elcock, 1998; Missimer et al., 2007; Xiao & Honig, 1999). It has also been
suggested that water-protein surface (Sterpone, Bertonati, Briganti, & Melchionna,
2009) and protein conformational flexibility (Kalimeri, Rahaman, Melchionna, &
Sterpone, 2013) are crucial factors for thermostability. There are also reports
focusing on how the type of amino acids would strengthen local interactions and
cause thermal stability. At this point, due to the diversity of these features, it is difficult
to sketch out a common and unique mechanism that explains how thermophilic
proteins keep their stability at temperatures above 300K. Our findings here suggest
that mutations bring on global effects in the protein flexibility affecting the distribution
of conformations in the ensemble. This change in the distribution is different for each
species of ANT and does originate from changes of the global dynamics of the
protein rather than from punctual, localized and specific non-bonded interactions.
This would correlate with the idea that cooperative networks might be responsible for
imposing restrictions to protein flexibility (Henzler-Wildman & Kern, 2007). In such
case, residues D80 and T130 are critically positioned nodes of such a network.
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CHAPTER II
THE ROLE OF PROTEIN STRUCTURE ENSEMBLE IN GPCR-DRUG
BINDING.
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Abstract
The development of structural biology has provided enough data to apply in silico
molecular docking techniques in early stages of drug discovery, drastically reducing
the cost and time involved in wet-lab experiments. This has been facilitated by
completion of the Human Genome Project, which has uncovered many targetable
and off-targetable receptors. In principle, docking techniques can not only be used in
potential drug targets, but also to predict the interaction of drug candidates with
possible off-target receptors. The goal of predicting adverse drug reactions (ADR) for
novel drug candidates is becoming a realistic objective. In this work, we present the
basis of a reliable framework for high-throughput ensemble-based docking which
allows

protein-drug

interaction

predictions

with

statistical

significance

and

consequently reduces the amount of false positive and/or negative hits. Crystal
structures and representative conformations of clustered trajectories for eight GPCRs
were examined, four of these proteins were subjected to a subsequent screening on
each conformational state of their respective trajectories; showing that virtual
screening is more efficient, when it is performed on a dynamic ensemble of target
conformations than on a single crystal structure.
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Introduction
In silico experiments on Adverse Drug Reaction
Molecular docking has been a very helpful tool to analyze, validate, and predict
binding of small molecules on proteins (Cerqueira et al., 2015; Taboureau, Baell,
Fernández-Recio, & Villoutreix, 2012). Its utility has increased with the availability of
super computers, protein structural data as well as the availability of large databases
of small molecules. The conformational selection paradigm has been the scaffold for
ensemble- docking under the premise that ligands will bind specific protein
conformations other than the basal crystal or NMR structures (Ellingson, Miao,
Baudry, & Smith, 2015; Evangelista et al., 2016; Meng, Zhang, Mezei, & Cui, 2011).
In order to obtain these other conformations, molecular dynamics (MD) techniques
are frequently employed to sample accessible states with a reasonable computing
time. In addition, the same approach could be employed to identify, analyze, or
dismiss off-target protein binding. Off-target proteins are responsible for adverse drug
reactions (ADR) exhibiting moderate to lethal effects. However, ADR caused by a
new drug candidate (Lounkine et al., 2012) typically appear at the pre-clinical or
clinical trials, and in a significant number of cases, candidates have to be removed
from the market due to reported ADRs (Bender et al., 2007; Pirmohamed,
Breckenridge, Kitteringham, & Park, 1998). Identifying off-target interactions in the
early stages of the drug discovery process is hence an important goal, even though
testing a very large number of proteins involved in the different metabolic pathways is
almost impossible. However, a panel of 44 proteins (Bowes et al., 2012) has been
proposed as responsible for about 75% of ADRs. This panel contains: 24 GPCRs,
eight ion channels, six intracellular enzymes, three neurotransmitter transporters, two
nuclear hormone receptors, and one kinase. Bowes' work implies that if a new
potential drug is discovered or designed, it must not bind to, or have a very low
affinity for these 44 proteins, in order to minimize the rise of ADRs. This set of
proteins can be a very good starting point to predict toxicity in silico via ensemble24

based docking simulations. However, this requires not only knowledge of the 3D
structure of the receptors, but also of the ensemble of conformations for each of
these proteins. Moreover, it also requires the design of a reliable procedure to
measure the performance of the virtual screening. The most common statistical
measures to identify the best receptor structures have been summarized and
described by Huang et. al. (Huang & Wong, 2016).
G-Protein Coupled Receptors
Most of those 44 proteins do not have a complete experimental structure. The initial
testing set in this work comprises the eight GPCR structures listed in Table 1.
GPCRs, also named heptahelical receptors, seven-transmembrane (7-TM) receptors,
or guanine-nucleotide-binding protein-coupled membrane receptors, are expressed
in eukaryotic organisms, and control a high number of regulatory processes. Since
GPCRs are located in the plasma membrane, they are accessible to not only their
natural ligands, but also to drugs, both antagonists and agonists. An important
characteristic of these proteins is the non-uniformity of expression in different cell
types and tissues, which provides special model of selectivity (Insel, Tang, Hahntow,
& Michel, 2007). These proteins are basically switches that activate various
responses after receiving some stimulus. Once the ligand binds the receptor, a
conformational change is performed and the GPCR will recruit, through structural
changes in the intracellular domains, a G-Protein to the inner leaflet of the cellular
membrane. This mechanism of signal transduction is crucial for many processes in
different tissues. Their malfunction might result in different kinds of monogenic
diseases, single defective genes in the autosomes, or genetic mutations (Insel et al.,
2007; Meyer, 2000). Alteration of GPCRs in number or structure/function will lead to
disorder in cellular signal transduction: up-regulation/hypersensitivity, Downregulation/desensitization, or receptor gene mutation. This is why fine-tuning is
crucial for GPCR’s functions and why it is one of the main targets of drugs.
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To date, all published GPCRs structures share a common 7-TM α-helices domain, as
shown on Figure II.1, and are located within the cellular membranes of different
organs (Palczewski & Orban, 2013). In spite of their almost identical structure, there
are several subtypes based on extracellular domain topology, on the type of Gprotein they activate, on activating ligands, on sequence similarity, or on function
(Park, Lodowski, & Palczewski, 2008).
Statistical Measurement of Performance
In order to sample conformational states beyond the experimental structures
obtained from the Protein Data Bank (PDB) (Berman et al., 2000), Coarse-Grained
(CG) Molecular Dynamics (MD) simulations were ran to generate one microsecond
trajectories for each of the eight GPCRs listed on Table 1. Docking calculations were
then performed on representative clusters for each protein. In a second set of
docking calculations, 3000 structures obtained from the trajectories for each protein,
i.e. without structural clustering, were used in docking calculations. The total number
of docking calculations on representative structures and full trajectories was about
2.3 million and 127.5 million, respectively.
Here, ensemble-based docking is used to screen many protein conformational states
against a ligand library of binding molecules (actives) and theoretically non-binding
molecules (decoys). The question that emerges is how to discriminate between
snapshots with significant contribution to conformational selection against those with
no significant contribution. In this work, I propose a statistical metric identify receptor
structures that significantly bind more active ligands than a random selection of
ligands. This method is based on Exploratory Data Analysis, developed in 1977 by
Tukey, to detect outliers based on the interquartile (IQR) values (Tukey, 1977).
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Figure II.1. Crystal Structure of ADORA2A.
Left Panel: In cyan, crystal structure of the ligand-bound form. PDB ID:3EML. In
green, modeled structure with intracellular loop and C-terminal completed.
Right Panel: Zoomed-in view of the binding site of the protein, in cyan, surface and
ribbon representation; and the ligand in purple bond-stick representation, 4-[2-[(7amino-2-furan-2-yl[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl)amino]ethyl]phenolthe,
DrugBank ID: DB0877.
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Methods
Collecting Structural data
GPCRs structures were downloaded from the RSCB Protein Data Bank, PDB IDs are
listed in Table 1. Ligands structures, actives and decoys, were downloaded from
DUD-E E (Mysinger, Carchia, Irwin, & Shoichet, 2012) for ADORA2A and ADRB2.
CC-DD database (Gatica & Cavasotto, 2012) was used to obtain the ligands for
CHRM2, HTR1B, HTR2B, OPRD1, and OPRK1, as summarized on Table II-1.
Preparation of Protein Structures for MD Simulations
The GPCR structures obtained from PDB are products of chimeric expression for
crystallization, domains of the structures that did not belong to the WT GPCR
sequence were deleted as well as co-crystallized ligands, and missing loops were
modeled and built using MODELER 9.10 (Fiser, Kinh Gian Do, & Sali, 2000). In
cases where the missing loop was in the opposite location of the binding site, in the
inner side of the membrane, and the number of missing amino acids was more than
20, these loops were not built.
Sampling conformations via Coarse-Grained modelling & MD simulations
In order to form an ensemble of GPCR structures, we sampled at least 5,000
conformations for each protein belonging to one microsecond of MD simulation. To
obtain this number of conformations in a reasonable computing time each protein
was mapped to coarse grained (CG) models and placed in a bilayer membrane. The
main components of the plasma membrane, as suggested by Leventis (Leventis &
Grinstein, 2010), were included in both inner and outer leaflets: phosphatidylcholine
(POPC), phosphatidylethanolamine (POPE),

phosphatidylserine (POPS), and

cholesterol (CHOL) at 42%, 25%, 14%, and 19%, respectively. Water and ions were
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added to equilibrate the system using martinize.py v2.5 and insane.py scripts
available at http://cgmartini.nl/index.php/tools2/proteins-and-bilayers

(Ingólfsson et

al., 2014; Monticelli et al., 2008; Pierole & Marrink, 2013; Wassenaar, Ingólfsson,
Böckmann, Tieleman, & Marrink, 2015) . Each of the systems, protein, membrane,
ions, and water, was reduced from ~125,000 atoms to CG ~14,000 particles. Next,
MD simulations were performed using Gromacs v5.1.0 (Berendsen, van der Spoel, &
van Drunen, 1995) for 1µs, saving frames every 200 ps. The setting parameters for
the energy minimization, equilibration, and production time were used as in
(Stansfeld et al., 2015). In order to select groups of similar structures from the
trajectories, Gromacs clustering tools and its built-in gromos method were used to
build clusters based on the Root Mean Square Deviation (RMSD) of the backbone
(Daura et al., 1999). The goal was to obtain a number of representative structures
such that the docking calculations can be done in an affordable computing time on
the Newton high performance computer cluster of The University of Tennessee,
Knoxville. According to Table II-1, there is an average of 10,000 active and decoy
small molecules per protein, thus, in order to generate 250,000 protein-ligand
complexes in a reasonable time, about 25 clusters were calculated for each protein.
Different RMSD thresholds were used to accomplish this purpose, for each protein
given in Table II-1. Once the representative structures were identified, they were
extracted from the trajectories using Gromacs tools, and back mapped to an all-atom
model using Backward v0.1 (Wassenaar, Pluhackova, Böckmann, Marrink, &
Tieleman, 2014). The second set of ensembles was composed of the all-atom
models obtained from back-mapping the entire trajectory, 5,000 conformations, of the
four proteins, ADORA2A, ADRB2, OPRD1, and OPRK1. These four proteins were
selected because they have a greater number of significant frames in each subset
analyzed after the docking on representative structures, except OPRK1, that has
zero significant frames in the 1.0% subset, but it contains more representative
structures than ADRB2 and OPRD1 in the other subsets (Table II-4). Thus, it was
expected to get more significant frames for these proteins than for the other four
proteins, HRH1, CHRM2, HTR1B, and HTR2B after the ensemble docking
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calculations on their 600 ns trajectories. CG-MD and back-mapping, were performed
on the Moldyn cluster at the UT/ORNL Center for Molecular Biophysics, Oak Ridge,
Tennessee.
Pre-docking preparation of receptors and ligands
VinaMPI, a high throughput docking program efficient on supercomputers and
developed in our laboratory (Ellingson, Smith, & Baudry, 2013), requires input files in
PDBQT format for both protein and ligands, and scripts from AutoDockTools (ADT)
v.1.5.6 (Sanner, 1999) were used to pre-process the conformations obtained from the
MD simulations. This pre-processing includes removing any atom other than the
protein’s and adding polar hydrogens atoms and Kollman charges. Ligands
structures were pre-processed, adding hydrogens and charges, and rotamers were
set according with the default method of ADT. The configuration files for the virtual
screening, receptors and ligands lists, were produced with the Python scripts
developed in the laboratory (Ellingson et al., 2013).
Docking on representative structures of clusters
The numbers of structures and ligands tested in this phase are listed in Table II-1.
This phase of the project was performed on the Newton high performance computer
cluster of The University of Tennessee at Knoxville. VinaMPI produced 2,292,040
combinations of protein-ligand complexes, each complex containing between 1 and
10 poses with corresponding calculated binding energies. The pose docked in the
binding site with the most favorable binding free energy is selected as a hit.
Docking on each frame of the trajectory
Four proteins were selected for molecular docking and submitted for ensemble-based
virtual screening to the super computer Titan at ORNL. The original idea was to use
5,000 frames of each protein, the same number that was used to obtain the
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representative structure after clustering, which were obtained after 1.0 us of CG-MD
simulations, however, due to computing time limitations, only the first 3,000
conformations were tested instead. To this end, these conformers were prepared in
the same way as the representative structures from the previous section. VinaMPI
generated 164 million protein-ligand complexes, each with 10 poses and their
corresponding binding energy, again the pose with the lowest energy is counted as a
hit.
Statistical Measurement for Conformation’s Performance
In order to establish a statistical threshold to decide whether docking results on a
particular frame are statistically significant, i.e. if it is selected by active compounds
beyond a random selection distribution, an outlier detection method was introduced
in the analysis. The Intequartile method (Salgado, Azevedo, Proença, & Vieira, 2016;
Tukey, 1977) defines the interquartile range (IQR) to set the lower and upper cut-off
values Q1-1.5*IQR and Q3+1.5*IQR, respectively (see Figure left panel in II-2).
Values below and above these thresholds are defined as outliers. An important
feature of this method is that does not depend on the symmetry of the distribution,
interqueatiles can be calculated on symmetrical and not symmetrical distributions.
Thus, if the number of active ligands bound to a particular frame is higher than the
upper cut-off, Q3+1.5*IQR, of a random distribution the docking results on this
particular frame will be statistically significant and this frame will be counted as a
“significant frame”. Values of this upper limit for each set of ligands belonging to their
respective proteins are shows in Tables II-3 – II-5 in the appendix section of this
chapter. For instance, the ligand library for ADORA2A comprises 844 actives and
10,899 decoys. If 5% of this pool, e.g. 587 molecules, is randomly selected, after
many assays, 42 actives and 522 decoys are expected in average, which then
implies there is still a significant probability to obtain 50, 60, or 100 active compounds
in any of the assays (Figure II.2, right panel).
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Once the significant frames have been identified, their list of receptor-ligand
complexes are merged together and ranked according to their binding energies.
Then, duplicates of active ligands are removed from the list, leaving only those with
the lowest free binding energy, ensuring that no duplicates are counted as number of
hits in the ensemble.

Figure II.2 Interquartile definition, and Probability distribution for random

selection at 5.0% for ADORA2A.

Left panel: Any set of data can be divided in four quartiles, containing 25% of the
data each. The interquartile range is defined as IQR = Q3-Q1.
Right panel: Random distribution for 5.0% (587 molecules, actives and decoys) of the
ligands library of ADORA2A. After many assays, every time 587 molecules are
selected from the library, in average 42 active ligands are obtained. The yellowcolored part of the distribution corresponds to a statistical random result and only a
number of actives > 59 (Q3 +1.5*IQR) would be deemed as statistical significant of a
non-random result.
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Table II-1 Set of GPCR proteins and their number of selected ligands for this work.
Protein Name

Gene
name

Actives

Decoys

Actives

Decoys

Clustering
RMSD
(A)

DUD-E

CC-DD

Number
of
Clusters

Number
of
Docking

Adenosine receptor A2A

ADORA2A

844

10899

443

17277

2

33

399262

β2-adrenergic receptor

ADRB2

447

15255

410

15990

2

18

298338

Histamine H1 receptor
Muscarinic acetylcholine receptor
M2
5-Hydroxytryptamine receptor 1B

HRH1

------

----------

86

3354

2

21

75680

CHRM2

------

----------

126

4914

1.9

32

166320

HTR1B

------

----------

113

4407

2.3

35

162720

5-Hydroxytryptamine receptor 2B

HTR2B

------

----------

227

8853

2

36

335960

δ-type opioid receptor

OPRD1

------

----------

377

14703

1.75

32

497640

κ-type opioid receptor

OPRK1

------

----------

307

11973

2.25

28

356120
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Results and Discussion
Docking on Clustered Structures
The IQR method was applied on four subsets of the ranked list for each frame, and
on the crystal structure: i.e. the top 0.5%, 1.0%, 5.0%, and 10.0% of compounds
predicted to bind. Interestingly, ADORA2A showed a dramatic improvement in
binding active ligands compared to the average of the random selection or crystal
structure at any percentage, see Figure II.3. In any subset, the crystal structure binds
less or about the same number than a random selection of compounds, while
docking experiments bind, by far, more active ligands, this likely because of the
number of significant frames found in each subset, 3, 4, ,8, and 16 for 0.5%, 1.0%,
5.0%, and 10.0%, respectively, as shown in Table II-4. For instance, at 1.0% of the
ranked list, the average of the random selection is 8 active compounds, while the
ensemble binds 99 of them; on the other hand, in 5.0% and 10.0% subsets the
enhancement reaches a remarkable 51% and 82% of the total active molecules,
respectively, as shown by Table II-3. ADRB2’s crystal structure and ensemble bind
more active compounds than random selection in any of the subsets as shown by
Table II.2 and Figure II-3. However, the major enhance of the ensemble for this
protein is achieved in the 10.0% subset, covering 17% and the total number of
actives, Table II-3, in spite of there is just one significant frame at this percentage for
this protein, Table II-4.
OPRD1, whose ensemble binds more active ligands than expected from the random
selection, and as many active ligands as the crystal structure at any of the
percentages analyzed, e.g. in the 1.0% subset the average of random selection is 4
actives, the docking experiments bound 13 active compounds. In the 10% subset,
the expected random selection is 38, while the ensemble binds 88 active ligands,
covering only 23.3% of the total number of active ligands, see Table II-3. In each
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case there is only one significant frame, Table II-4, and it is the same conformation at
12.8 ns. OPRK1’s crystal structure and ensemble represent an interesting case,
because the crystal structure binds less active ligands than a random selection in all
the subsets; while the ensemble does not contain significant frames in the 1%
subset, however, in the 5% and 10% subsets the ensemble binds at least three times
the random selection with 2 and 3 significant frames, Table II-4, covering 14% and
33%, respectively, of the total number of active compounds in the pool, as displayed
by Table II-3.

Figure II.3 Unique Actives docked in clustered conformations.
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Table II-2 Number of unique active ligands selected via: Random Selection, docked in crystal structure, in
representative structures of clustered frames, and in 3000 frames of 600 ns of MD trajectory.
Ligands

Protein

Average of Actives in
Random Selection

Actives

Decoys

Total

0.5
%

1.0
%

5.0
%

10.0
%

0.5
%

ADORA2A

844

10899

11743

4

8

42

84

ADRB2

447

15255

15702

2

4

22

45

86

3354

3440

0

1

4

CHRM2

126

4914

5040

1

1

HTR1B

113

4407

4520

1

HTR2B

227

8853

9080

OPRD1

377

14703

15080

OPRK1

307

11973

12280

HRH1

Unique Actives in
significant frames in
clustered data

Actives in Crystal
Structure

Unique Actives in
significant frames in 600
ns of trajectory

1.0
%

5.0
%

10.0
%

0.5
%

1.0
%

5.0
%

10.0
%

0.5
%

1.0
%

5.0
%

10.0
%

0

2

39

98

50

99

432

693

450

550

802

836

9

14

53

96

9

12

42

76

56

80

267

392

9

3

6

19

26

0

6

0

16

6

13

0

2

9

20

0

0

13

23

1

6

11

0

0

4

13

0

0

0

0

1

2

11

23

5

9

24

39

0

9

49

39

2

4

19

38

8

17

53

85

7

13

56

88

79

125

243

276

2

3

15

31

0

0

4

12

8

0

45

104

58

69

168

247
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Table II-3. Percentage of the Total Number of Actives bound by the Crystal Structure, Representative
structures, and ensemble from trajectory.
Percentage of Actives Bound by
Crystal Structure in each subset

Percentage of Actives Bound by
Cluster in each subset

0.5%

1.0%

5.0%

10.0%

0.5%

1.0%

5.0%

10.0%

0.5 %

1.0 %

5.0 %

10.0 %

0.0

0.2

4.6

11.6

5.9

11.7

51.2

82.1

53.3

65.2

95.0

99.1

447

2.0

3.1

11.9

21.5

2.0

2.7

9.4

17.0

12.5

17.9

59.7

87.7

86

3.5

7.0

22.1

30.2

0.0

7.0

0.0

18.6

CHRM2

126

0.0

1.6

7.1

15.9

0.0

0.0

10.3

18.3

HTR1B

113

0.0

0.0

3.5

11.5

0.0

0.0

0.0

0.0

HTR2B

227

2.2

4.0

10.6

17.2

0.0

4.0

21.6

17.2

OPRD1

377

2.1

4.5

14.1

22.5

1.9

3.4

14.9

23.3

21.0

33.2

64.5

73.2

OPRK1

307

0.0

0.0

1.3

3.9

2.6

0.0

14.7

33.9

18.9

22.5

54.7

80.5

Protein
ADORA2A
ADRB2
HRH1

Total
of
Actives
844

Percentage of Actives Bound by
Trajectory in each subset
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Table II-4. Number of significant frames found after docking on clustered data
and trajectory for each subset.
Number of Significant Frames in
Cluster

Number of Significant Frames in
Trajectory

0.5%

1.0%

5.0%

10.0%

0.5%

1.0%

5.0%

10.0%

ADORA2A

3

4

8

16

166

187

508

817

ADRB2

2

1

1

1

20

21

84

128

HRH1

0

2

0

1

CHRM2

0

0

1

1

HTR1B

0

0

0

0

HTR2B

0

1

3

1

OPRD1

1

1

1

1

33

34

35

41

OPRK1

2

0

2

3

71

23

40

70

Protein

Clusters obtained from CG-MD simulations of HRH1, CHRM2, HTR1B, and HTR2B
do have at least one subset, in which does not contain significant frames. They were
discarded for ensemble docking on trajectory of 3,000 frames.
Clusters obtained from ADORA2A, ADRB2, and OPRD1 have at least one significant
frame in each subset; whereas, OPRK1 has none significant frames in 1.0% subset,
however, this protein contains in total seven significant frames in the other subsets.
These four proteins were then subjected to an ensemble docking on 3,000
conformations of a 600 ns trajectory from CG-MD simulations.
Number of significant frames of the four proteins selected for ensemble docking on
the entire 600 ns trajectory increased remarkably compared to number of significant
frames obtained in the representative structures of the clustered data.
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Docking on non-Clustered Trajectory
Docking experiments were performed on 600 ns of trajectory without structural
clustering four proteins: ADORA2A, ADRB2, OPRD1, and OPRK1. In total, 3000
conformations of each of these proteins were tested against their respective number
of ligands according with Table II-2. The number of significant frames was
dramatically increased with respect to the clustered data, i.e. in the 5.0% subset from
only 8 significant frames to 500 as shown in Table II-4. This also leads to an increase
in the number of unique actives docked in those significant frames, as shown in
Tables II-2 and II-3, and Figure II.4. The ADORA2A’s ensemble showed again the
best improvement of the ensemble-base docking with respect to a random selection
or docking on the crystal structure at any of the percentages (see left upper panel in
Figure II.4). The hits obtained in each 0.5%, 1.0%, 5.0% and 10.0% cover the 53%,
65%, 95%, and 99%, respectively, of the entire set of active ligands for this protein.
This is pretty remarkable, since the ensemble binds a number of active ligands far
higher than a random selection or the crystal structure, this is also due to the
increase in the number of significant frames as shown in Table II-4. This implies that
a new compound can be tested, and the probability to bind the protein will be
assessed much better than using the crystal structure. The second case, ADRB2
(right upper panel of Figure II-4) shows improvements in every subset respect to the
crystal structure and up to 20 times with respect to a random selection. In 0.5% and
1.0% subsets the conformational states provided by the non-clustered trajectory bind
59% and 87% of total active molecules, 447, in the library for this protein, Table II-3.
The hits obtained by the OPRD1’s ensemble are by far higher than a random
selection and show also improvements with respect to the clustered conformations
and crystal structure (left lower panel in Figure II-4). In each of the subsets the
ensemble provided by the non-clustered MD simulations covers 21%, 33%, 64%, and
73% of the entire ligands in the library for this protein, versus the 2%, 3%, 15%, and
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23% covered by representative structures from the clustered simulation, Tables II-2
and II-3.
The OPRK1 ensemble (right lower panel in Figure II.4) binds many more actives than
the crystal structure at any of the subsets, these subsets cover 19%, 22%, 54%, and
80% of the active ligands library for this GPCR (Tables II-2 and II-3) which is quite
remarkable if compared to the percentage of actives bound to the crystal structure or
the representative structures provided by clustering.

Figure II.4 Docking results on four GPCRS performed on frames from 600 ns of
MD trajectory.
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These results lead to the question, why are ensemble docking calculations more
efficient for some GPCRs? The first explanation comes from the MD trajectories.
Depending on the dynamics of each particular protein, the 600 ns of MD trajectory
could sample a large variety of conformations, or not. One way to assess this is the
atomic root mean square deviation values (RMSD) values of the whole structure in
each case, shown in Figure II.5. This figure shows that OPRD1 does not display as
much structural variation as the other three proteins, the highest volume for OPRD1
is about 260 Å3, while ADORA2A or OPRK1 samples conformations with volumes
about 500 Å3, generating less conformations potentially selected by ligands. This
might explain why docking results from representative MD structures of this protein
are very similar to results obtained using the crystal structure only, in all the subsets
below 24%, (Table II-3). Docking results in the 10% subset for conformations in the
trajectory identify 73% of the total actives for this protein. Less conformations
sampled, less chances to be selected by ligands, implying that many compounds,
about 27% of the total library for this GPCR, in the 10% subset of the ranking did not
“find” the right conformation of the protein to form the complex.
ADORA2A, ADRB2, and OPRK1, on the other hand, exhibits RMSD variations
greater than OPRD1, hence, the MD is sampling more conformational states. This
would explain why these three proteins are selected by more active molecules at any
of the percentages analyzed, as more conformational states are sampled, more
active compounds will bind the protein. ADORA2A results are particularly interesting,
the ensemble provided by clustering includes 33 structures and 16 of them are
significant (Table II-4), these conformers can bind 82% of the total active ligands in
the 10.0% subset. Even better, the trajectory’s ensemble binds 99% of the total
ligands library for this protein when the equivalent subset, 10.0%, is analyzed (Table
II-3), and 817 significant frames were found in this subset. ADRB2’s ensemble
coming from clustering is the least efficient of the four proteins, this ensemble’s
efficiency is worse than the crystal structure. In the first two subsets, 0.5% and 1.0%,
the ensemble built for this protein exhibit 6-times more selected active compounds
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than a random selection, they only cover 12% and 17% of the entire library of active
ligands for this protein. However, in the 10.0% subset, the ensemble obtained for this
protein is the second most efficient, covering 87% of its ligands library (Table II-3),
and up to 128 significant frames in the 10.0% subset. OPRK1‘s ensemble presents
the highest variation in the RMSD values, Figure II.5, and bind even less active
molecules than OPRD1’s ensemble for the 0.5%, 1.0%, and 5.0% subsets. Since the
RMSD is higher in this case, it is supposed this structure is sampling more
conformations, however, frames that were not significant in the mentioned subsets
turned out to be significant in the 10.0% subset, reaching to cover 80% of the active
molecules library for this GPCR, see Table II-3.
RMSD is an indicator of flexibility of the whole protein, and the lack or abundance of
dynamics in the structure might be crucial for GPCR and its affinity for ligands, as
suggested by (Lebon, Warne, & Tate, 2012; Shahane, Parsania, Sengupta, & Joshi,
2014). In general, there are several causes for variation of affinity between one
GPCR and another, e.g. nature of residues in the binding site (Gether & Kobilka,
1998), chemical nature of ligands, cell membrane constituents (Ghanemi, He, & Yan,
2013). Small structural changes in the binding pocket could also be critical in the
receptor function (Deupi & Kobilka, 2010). Thus, to get some insights about the
possible contributions to the ligand binding of the volume of the binding site, binding
site’s volume was calculated on the 600 ns trajectory for the four systems using the
trj_cavity software (Paramo, East, Garzón, Ulmschneider, & Bond, 2014). The results
(Figure II.6) show that while ADORA2A, ADRB2, and OPRK1 sample conformations
with a larger binding site than in their correspondent crystal structures, OPRD1
samples conformational states with a smaller cavity than in the crystal structure.
Another interesting feature about ADORA2A is that the volume of the cavity changes
from about 200 Å3 to 430 Å3 at 250 ns (upper left panel in Figure II.6). This difference
in flexibility could have some contribution to the fact that ADORA2A’s ensemble can
bind more active ligands than ADRB2 or OPRD1 ensembles in any of the analyzed
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subsets shows in Table II-3. However, OPRK1 samples the same variation in the
volume of the binding pocket, lower left panel in Figure II.6, but even in the 10.0%
subset, this ensemble cannot bind as many ligands as ADORA2A’s ensemble does,
and covers 80% of the total number of its active ligands in the library. Even though
the binding site volume does not fully explain the difference in the number of ligands
selecting these proteins, it might have some contribution to some of these cases.
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Figure II.5 RMSD of the α-Carbons for the four GPCRs as function of
simulation time.

Figure II.6 Volume of binding site for each of the four systems as
function of time.
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Conclusions
Ensemble-base docking as a tool for virtual screening has been shown to be a
promising technique to predict protein-drug interactions. The results here show that
ensemble-based docking on conformations from a trajectory of MD simulations leads
to improvements in predicting ligand binding with respect to docking calculations on
single crystal structures. Importantly, the procedure proposed here discriminates
statistically between conformational states are selected by ligands above a random
selection of compounds. Thus, prediction of ADR via ensemble-based docking is
foreseen as a feasible method once structural significant species are identified. Still
yet, its high computational cost might make this technique too much expensive for
daily use, e.g. docking calculations on ADORA2A’s 3,000 conformations against
about 11,7000 ligands required approximately 8 million hours-processors, which is
still unaffordable for most of the laboratories working on drug discovery. As discussed
in the previous section, active molecules will bind certain conformations more
frequently than others. It is imperative to develop a reliable method to find those
“magic snapshots” that will be selected by most of the compounds. So far, there are
no reports of a trustworthy conformational coordinate that will allow us to cluster the
whole set of conformations sampled by the MD simulation, such that the docking
calculations be reduced, saving time, money, and extending the search space of offtarget proteins. This, however, will be an important future research direction, for rest
of the proteins that have known active/decoys and experimental structure available
and are part of the 44 protein panel relevant to ADRs, conformations selected by
ligands will be identifiable by our statistical method.
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Appendix
Table II-5. Thresholds to determine outliers for ADORA2A and ADRB2 in random
selection distributions.
ADORA2A
Actives:
#Percentage%
Expected sample
size
Expected Actives.
#Upper Value
ITQ
ADRB2
Actives:
#Percentage%
Expected sample
size
Expected Actives.
#Upper Value
ITQ

844 Decoys:
10899 Total:
0.5 %
1.0 %
5.0 %
10.0 %
59
4

117
8

587
42

1174
84

9

17

59

107

447 Decoys:
15255 Total:
0.5 %
1.0 %
5.0 %
10.0 %
79
2

157
4

785
22

1570
45

7

11

35

63

11743

15702

Table II-6. Thresholds to determine outliers for HRH1 and CHRM2 in random selection
distributions.
HRH1
Actives:
#Percentage%
Expected sample
size
Expected Actives.
#Upper Value ITQ
CHRM2
Actives:
#Percentage%
Expected sample
size
Expected Actives.
#Upper Value ITQ

86 Decoys: 3354 Total:
0.5 % 1.0 %
5.0 % 10.0 %
17
0
3

34
1
3

172
4
11

344
9
15

126 Decoys: 4914 Total:
0.5 % 1.0 %
5.0 % 10.0 %
25
1
3

50
1
6

252
6
13

3440

5040

504
13
23
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Table II-7. Thresholds to determine outliers for HTR1B and HTR2B in random selection
distributions.
HTR1B
Actives:
#Percentage%
Expected sample
size
Expected Actives.
#Upper Value ITQ
HTR2B
Actives:
#Percentage%
Expected sample
size
Expected Actives.
#Upper Value ITQ

113 Decoys:
0.5 % 1.0 %
23
1
3

45
1
6

227 Decoys:
0.5 % 1.0 %
45
1
6

91
2
7

4407 Total:
10.0
5.0 % %
226
6
12

452
11
20

8853 Total:
10.0
5.0 % %
454
11
20

4520

9080

908
23
36

Table II-8. Thresholds to determine outliers for OPRD1 and OPRK1 in random
selection distributions.
OPRD1
Actives:
#Percentage%
Expected sample
size
Expected Actives.
#Upper Value ITQ
OPRK1
Actives:
#Percentage%
Expected sample
size
Expected Actives.
#Upper Value ITQ

377 Decoys: 14703 Total:
10.0
0.5 % 1.0 %
5.0 % %
75
2
7

151
4
10

754
19
32

1508
38
55

307 Decoys: 11973 Total:
10.0
0.5 % 1.0 %
5.0 % %
61
2
4

123
3
8

614
15
26

15080

12280

1228
31
45
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CHAPTER III
OPPORTUNITY AND CHALLENGES OF ENSEMBLE-BASED
DOCKING IN TOXICITY
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Abstract
The increase of computational power and production of data lead the scientific
community to exponential progress in many fields of science. One of the most
impressive advances comes from the increase of computational power through
supercomputing. This has improved and expanded molecular simulations in structural
biology. Nowadays it is possible to run long single molecular dynamics simulations,
one microsecond, of about 100 thousands atoms in only 24 hours on a
supercomputer. Similar improvements have been achieved in molecular docking;
massive dockings can screen now millions of compounds in the same period of time.
This represents an excellent opportunity to study and predict protein-drug interactions
on a scale not reachable previously. However, this progress also brings a challenge;
how to manage the immense amount of data generated by these simulations, and
how to correlate this data with the experimental data. So far, techniques from data
mining and machine learning have been useful in the integration and information
crossing of all these sources. These techniques and the treatment of information will
continue to be important and crucial for next years in order to get solutions and
insights of many biological problems.

Introduction
Adverse Drug Reactions (ADR) can have different mechanisms: polymorphism in
genes that code enzymes involved in drug metabolism (Meyer, 2000), immune and
non-immune mechanisms producing hypersensitivity responses (Dao, Su, & Chung,
2015; Riedl & Casillas, 2003), or other mechanisms reviewed elsewhere (Edwards &
Aronson, 2000). However, in fine, the molecular mechanisms mediating ADR always
involves protein-drug interactions. This represents the most difficult challenge in the
drug design/discovery field. This is because any new drug candidate has a potentially
high chance to bind any off-target protein. How to predict whether a drug candidate
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will bind an off-target protein? An important advance was provided in 2012, when in
vitro drug screening led to proposing a panel of 44 proteins as a set to test ADR
(Bowes et al., 2012). Even though this is great progress, it is still too expensive and
time consuming to test the, typically thousands of, drug candidates against this panel
of proteins. The alternative is, of course, in silico screening. However, this task faces
a challenging biological fact, proteins do not exist in only one conformation, and
actually, such a conformation might differ from the experimental structure obtained by
NMR or X-Ray diffraction (Hilser, Garcia-Moreno E., Oas, Kapp, & Whitten, 2006).
Thus, in order to examine whether any molecule would bind a particular protein, it is
necessary to test as many conformational states as possible, providing better insights
on the protein-drug/candidate interaction, as described in the previous chapter.
Efforts to predict general protein-drug binding has been extensive, numerous
software applications have been developed to this end, for example, Autodock, Vina,
VinaMPI, Gold, Dock, and some others (Pagadala, Syed, & Tuszynski, 2017). The
current challenge is to use any of these applications to perform massive highthroughput docking and build a reliable model to decide whether or not a molecule,
potential drug candidate, will bind the protein. This is difficult, since at the molecular
level there are many factors involved: protonation states of both ligand and receptor,
contributions of solvent, conformational entropy, ligand’s flexibility, building of energy
function, score function, etc. Additionally, one must consider how to rank the massive
output obtained from these in silico experiments, and make sure that the data
provided is reliable beyond the random distribution. The next sections will describe
what I think the future directions on ensemble-based docking as virtual screening are,
and their role in toxicity predictions, and addressing a particular challenge: how to
share and learn from our and others experiences taking into account the increasing
amount of information generated every day all over the world. The tools to handle this
massive amount of information are data mining and learning machine technologies,
whose principles and applications are also described.
.
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Current State of Ensemble-base Docking and ADR
In silico experiments of protein-drug interactions have found their most common
applications in docking simulations in which a protein is used in a structure-based
approach to computationally identify the molecules from a collection predicted to
have the most favorable binding energies, and hence to bind more strongly to the
target. This is an approach used in the initial steps of drug discovery, where new
hits/leads are needed. In silico screening thus helps to prioritize chemicals for
experimental assays (Jorgensen, 2009). Our laboratory has also used this approach
to identify compounds capable of modulating the interactions between proteins
responsible for coagulation cascade, Factor Xa (FXa) and Factor Va (FVa). Drugs
that inhibit enzymatic functions of FXa already exist, nonetheless, their safety profile
is extremely narrow, and have shown to be difficult to use even in hospitals. This
project has led to the discovery of novel molecules that can bind to FXa’s surface and
modulate the interactions with FVa, without affecting FXa’s enzymatic functions
(Kapoor et al., 2016).
However, narrowing search space or validating potential drug candidates have only
been the initial applications of docking. For a long time, the target-centric approaches
ignored the physiological context and the cellular composition, which made docking
calculations less useful, particularly when the predicted results were could not be
validated by biochemical assays or pre-clinical and clinical trials (Iskar, Zeller, Zhao,
van Noort, & Bork, 2012). Ensemble-based docking can now be part of a more
integral pharmacological strategy, including high-throughput virtual screening of not
just the many conformations of the target protein, but also of all the possible proteins
responsible for a toxic response. For instance, during the latest Ebola outbreak, an
integrated strategy was employed to seek a potential drug. Among 1,766 drugs
approved by the FDA, 259 experimental drugs were screened looking for a potential
compound that could inhibit Ebola virulence or replication. A protocol including three
computational approaches was used: proteome-wide ligand binding site comparison
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(Xie & Bourne, 2007), molecular docking, and MD simulations, resulting in
identification of Indivinavir, a known HIV protease inhibitor, as a likely reducer of
Ebola virulence, and some other anti-fungal and anti-viral drugs as potential RNA
polymerase inhibitors (Z. Zhao, Martin, Fan, Bourne, & Xie, 2016). The same year
another study predicted emodin-8-beta-D-glucoside from the Traditional Chinese
Medicine Database as a potential inhibitor of viral protein 40 (VP40) from Ebola after
an integrated work carried out using molecular docking, public databases of toxicity
like Protox (Drwal, Banerjee, Dunkel, Wettig, & Preissner, 2014), and MD simulations
to validate docking findings (Karthick et al., 2016). These experiences show that
ensemble-based docking has already been used as part of an integrated set of
computational tools to identify/propose compounds to treat a particular disease,
either in repurposing FDA-approved drugs, or filtering experimental drugs that could
result in adverse reactions.
A different strategy to predict/test ADR is proposed by LaBute et.al (Labute et al.,
2014), in his work in which combined information from DrugBank (Law et al., 2014;
Wishart, 2006), Side Effect Resource (SIDER) (Kuhn, Campillos, Letunic, Jensen, &
Bork, 2010) and molecular docking were used to train a machine learning model with
906 small molecules and 409 protein targets, resulting in predictions that are
comparable in quality to those obtained using the same model over publicly available
and experimentally-derived drug-protein interaction data. The combination of
molecular docking software and machine learning systems has been also employed
to

integrate

structure-based

drug

design

and

quantitative

structure-activity

relationships (QSAR) into a learning model to improve the performance of binding
site recognition, using to this end 139 different kinases and 33 inhibitors. The
inclusion of machine learning enhanced the binding prediction of the molecular
docking software and therefore the identification of potential targets (Hsin, Ghosh, &
Kitano, 2013). What these examples show is that machine learning methods are
already part of different studies on the way to enhance not just molecular docking
scores, but also to identify off-target proteins responsible for ADR. Currently, virtual
57

and experimental high-throughput screenings of chemical libraries have become the
major tools not only to identify on-target hit compounds, but also off-target hits.
Additionally, relatively new techniques have been incorporated to the pool of
methods in drug discovery: next-generation sequencing to identify new targets,
biomarkers, polypharmacology to identify networks by modulating multiple targets.
Thus, effective drugs can be developed potentiating on-target hits and avoiding offtarget binding (Anighoro, Bajorath, & Rastelli, 2014; Taboureau, Baell, FernándezRecio, & Villoutreix, 2012).

Integration of Molecular Tools and Databases
The inclusion of MD simulations in a docking strategy could be an important
contribution for drug discovery if it were less computationally expensive (H. Zhao &
Caflisch, 2015). However, GPU technology makes MD simulations more affordable in
terms of computing time (Kutzner et al., 2015; Salomon-Ferrer, Götz, Poole, Le
Grand, & Walker, 2013). Thus, GPU-based MD software like Gromacs and Amber
are already being used in research on different fields, such as solid-liquid phase
transition (Nomura, Oikawa, Kawai, Narumi, & Yasuoka, 2014), MD simulations of
the DNA duplex (Galindo-Murillo, Roe, & Cheatham, 2015), and protein folding
(Bermudez, Mortier, Rakers, Sydow, & Wolber, 2016). GPU-based MD simulations
will be extremely useful in validating findings from docking calculations in a faster
way. Similarly, in the same way VinaMPI and VinaLC have boosted virtual screening
in drug discovery through parallelization and scalability in clusters and super
computers, it is expected that molecular docking software based on GPU technology
will increase the performance of ensemble-base docking. In a similar field, there is
already GPU-based docking software for protein-protein interactions, for instance,
Megadock-GPU (Shimoda, Ishida, Suzuki, Ohue, & Akiyama, 2013), PIPER14
(Landaverde & Herbordt, 2014). Nonetheless, there is not yet a GPU-based docking
software for virtual screening of ligand libraries. Since ensemble-based docking is
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now used not only to identify/validate on-target protein-ligand interactions, but also to
identify possible off-target protein binding, developing this kind of software should be
one of the top priorities in the field. The availability of GPU technology will make highthroughput molecular docking more affordable, in contrast to the current situation
where performing a virtual screening of thousands of compounds over thousands of
conformational states, generating millions of receptor-ligand complexes, requires
computational power only found in supercomputers.
Developing a clustering method to find significant frames in the conformational space
is still a pending task; an efficient conformation coordinate will characterize changes
in the structure of the protein during the sampling process. This, of course, will
reduce the search space for molecular docking calculations. Root Mean Square
Deviation (RMSD) is the most common parameter to measure variations in the
protein structure. Depending on the region or domain in the structure, the RMSD can
be a measurement for any particular set of atoms, whether it’s the binding site,
secondary structure, or the entire protein. Typically, C-α atoms are used as a metric
to measure changes in the structure, however, this metric can miss some changes.
For instance, two conformations of the same protein can exhibit a RMSD of 2.3 Å
with respect to a reference structure. However, the first conformation could have
those 2.3 Å of variation in a loop, while the second conformation gets the same
RMSD due to an alpha helix domain 20 Å apart from the loop. Even though the
RMSD values are identical, the conformational changes will originate from totally
different conformations. Markov state models have been used to characterize protein
conformations (Chodera & Noé, 2014; Lane, Bowman, Beauchamp, Voelz, & Pande,
2011), and principal component analysis (Balsera, Wriggers, Oono, & Schulten,
1996; Papaleo, Mereghetti, Fantucci, Grandori, & De Gioia, 2009; Sittel, Jain, &
Stock, 2014), or some particular geometric parameter can also be used. Therefore,
an appropriate conformational coordinate is necessary to reduce the number of
conformational states subject of molecular docking, otherwise, this problem will stay
intractable.
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Progress in any field of science has been achieved due to the sharing of information.
Biological sciences, in particular, have experienced rapid progress in different
disciplines: structural biology, genomic, proteomic, genetics, drug discovery,
simulation software, etc. Most of the databases and tools used to share and search
data of interest are integrated by the National Center for Biotechnology Information
(NCBI). On the other hand, some public databases, which are very important for
research, are not part of NCBI: Protein Data Bank, The Cambridge Structural
Database, Database of Useful Decoys-Enhanced (DUD-E), etc. Since this work is
particularly interested in adverse drug reactions, I found particular interest and
promise in some of these databases:
DrugBank: Database of drug and drug targets with chemical and pharmacological
information (Wishart, 2006).
https://www.drugbank.ca/
DUD-E: directory of active ligands and decoy molecules for each ligand and their
respective targets (Mysinger, Carchia, Irwin, & Shoichet, 2012).
http://dude.docking.org/
SIDER: Information on marketed medicines and their adverse drug reactions;
including side effect frequency, side effect classification, and in some cases drugtarget relations (Kuhn, Letunic, Jensen, & Bork, 2016).
http://sideeffects.embl.de/
Two interesting initiatives, but apparently not well maintained sites are:
PDBbind: Experimentally measured binding affinity data for protein-ligand complexes
from the Protein Data Bank (Wang, Fang, Lu, Yang, & Wang, 2005).
http://sw16.im.med.umich.edu/databases/pdbbind/index.jsp
Platinum: Structural database of experimentally measured effects of mutations on
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protein-ligand complexes (Pires, Blundell, & Ascher, 2015).
http://biosig.unimelb.edu.au/platinum/
These databases contain important information for drug discovery research.
However, besides the common format for structures of molecules, there is not a
standard format to share other information related to protein-ligand complexes, such
as affinity constants, dissociation constants or clinical and toxicity information. To
integrate all these web servers is, of course, utopic. Nonetheless, it would be
extremely helpful for the scientific community to define standard formats to share this
kind of data. Moreover, since these databases only gather information, it is crucial to
fill them with experimental and computational data, which assists investigators in the
different stages of the drug discovery/design process, and even later, in the preclinical and trial phases (Taboureau et al., 2012). Of particular importance is the
expansion of the experimental data beyond the panel proposed by Bowes (Bowes et
al., 2012). This will likely help in the identification of other proteins responsible for
adverse drug reactions.
For the scientific community to take advantage of the integration of all these different
sources of information, it is necessary to use two essential technologies: data mining
and machine learning. Data mining is the automatic harvesting of information from
large databases in order to find unknown patterns or knowledge (Lavecchia, 2015).
This usually leads to models to explain a particular phenomenon. However, when
data increases in amount and type, the model needs adjustments and/or
reformulations. Dealing with this kind of problem manually is time and resource
consuming, Machine Learning is a technology that is capable of addressing these
sorts of problems, this is a field of study that gives computer the ability to learn
without being explicitly programmed (Samuel, 1959). As more data become
available, machine learning can be used to process new types or data, making the
machine learning more favorable than manual programming in terms of time, and
consequently cost (Domingos, 2012). This technique has already been employed to
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deal with increasing amounts of complex data in applications such as web searches,
spam filters, stock trading, drug design, as well as in proteomics and genomics
(Lavecchia, 2015; Li, Wu, & Ngom, 2016).
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CONCLUSIONS
Computational approaches have become an important tool to understand molecular
mechanism of many properties in proteins. Particularly remarkable has been the role
of MD simulations of full-atom models or coarse grained models. This technique
combined with the use of supercomputers has increased our knowledge of protein
dynamics and how different conformations of proteins coexist instead of only one
single structure. This ensemble can also vary as interactions with other molecules
occur. Chapter I presented a case, Aminoglycoside nucleotidyltransferase 4’, where
changes in the environment modifies the structures distribution, e.g. as temperature
is increased the distribution of conformational states changed. However, these
changes are not trivial to identify. A reduction of dimensionality, via principal
component analysis, was performed to characterize these modifications in the
ensemble. Two main principal components were identified and used to characterize
the protein structural ensemble. Potential of mean force, using the first two principal
components as conformation coordinates, was then calculated to visualize a free
energy landscape of the ensemble at three different temperatures, these energy
landscapes show how the ensemble change as the temperature increases, or as
point mutations are introduced in the system at a given temperature. The results also
suggest that mutations bring on global effects in protein flexibility affecting the
distribution of conformations in the ensemble.
Chapter II describes the work done to build a reliable method to analyze results
coming from ensemble-based docking calculations. The use of ‘outliers’, as defined
by the Exploratory Data Analysis field, has been useful to discriminate conformations
that are selected by more ligands than by a random selection. For this purpose four
G-Protein Coupled Receptors were used as model systems, these four proteins have
been reported as part of a set of 44 proteins responsible for about 75% of adverse
drug reactions. Ensembles of representative structures were examined as well as
ensembles containing 3,000 conformations provided by coarse grained molecular
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dynamics simulations. The results indicate that the method developed in this work is
more efficient than a random selection in all the cases. Application of this method on
docking results from representative structures produced a remarkable improvement
respect to random selection or from using single crystal structure for two proteins.
When this technique was performed on 3,000 conformations for each protein, results
showed a dramatically improvement with respect to random selection, of using a
single crystal structure, and docking on representative structures, correctly identifying
up to 73%, 80%, 87%, and 99% of the chemicals that are known to bind these
proteins off-targets, leading to adverse reactions.
A review of the current state and future directions in the field of molecular docking
and other resources as tools to predict adverse drug reactions is presented in
Chapter III. The integration of data and algorithms has been a strategy that has
allowed progress in numerous fields of biology. In particularly, public databases with
information about drug toxicity are now available and they can be used together with
structural biology data to speed up the prediction of such effects in the drug discovery
process. Ensemble-based docking in this context represents not only an option to
speed up the drug design/discovery process but a necessity. However, its high
computational cost still makes this technique affordable only for laboratories with
access to supercomputing resources and expertise. Additionally, the generation of
such massive amount of data implies also innovation in other areas of science, such
as data mining and machine learning. Proficiency in managing this amount data will
determine the future of in silico prediction of adverse drug reactions.
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